

Xue Ke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8353118/publications.pdf>

Version: 2024-02-01

9
papers

423
citations

1040056

9
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

767
citing authors

#	ARTICLE	IF	CITATIONS
1	Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment. <i>Acta Biomaterialia</i> , 2017, 51, 374-392.	8.3	90
2	Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 181-191.	2.8	85
3	Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. <i>International Journal of Pharmaceutics</i> , 2015, 478, 553-568.	5.2	73
4	GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 5125-5147.	6.7	43
5	Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 2583-2597.	7.5	33
6	Development of low molecular weight heparin based nanoparticles for metastatic breast cancer therapy. <i>International Journal of Biological Macromolecules</i> , 2018, 112, 343-355.	7.5	31
7	A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis. <i>Journal of Drug Targeting</i> , 2015, 23, 335-346.	4.4	28
8	Low molecular weight heparin-based reduction-sensitive nanoparticles for antitumor and anti-metastasis of orthotopic breast cancer. <i>Biomaterials Science</i> , 2018, 6, 2172-2188.	5.4	26
9	Reduction-responsive modification-induced higher efficiency for attenuation of tumor metastasis of low molecular weight heparin functionalized liposomes. <i>RSC Advances</i> , 2016, 6, 49250-49262.	3.6	14